ATE551345T1 - Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on - Google Patents
Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-onInfo
- Publication number
- ATE551345T1 ATE551345T1 AT05799991T AT05799991T ATE551345T1 AT E551345 T1 ATE551345 T1 AT E551345T1 AT 05799991 T AT05799991 T AT 05799991T AT 05799991 T AT05799991 T AT 05799991T AT E551345 T1 ATE551345 T1 AT E551345T1
- Authority
- AT
- Austria
- Prior art keywords
- methylüphenylü
- cdüindol
- azepinoä5
- methylamino
- tetrahydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Surgery (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61245904P | 2004-09-22 | 2004-09-22 | |
| US67929605P | 2005-05-09 | 2005-05-09 | |
| PCT/IB2005/002941 WO2006033007A2 (en) | 2004-09-22 | 2005-09-12 | Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE551345T1 true ATE551345T1 (de) | 2012-04-15 |
Family
ID=35526956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05799991T ATE551345T1 (de) | 2004-09-22 | 2005-09-12 | Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7268126B2 (de) |
| EP (1) | EP1799685B1 (de) |
| JP (1) | JP2008513436A (de) |
| KR (1) | KR100853601B1 (de) |
| AR (1) | AR051296A1 (de) |
| AT (1) | ATE551345T1 (de) |
| AU (1) | AU2005286191B2 (de) |
| BR (1) | BRPI0516766A (de) |
| CA (1) | CA2581025C (de) |
| ES (1) | ES2382950T3 (de) |
| IL (1) | IL181463A (de) |
| MX (1) | MX2007002461A (de) |
| NO (1) | NO337938B1 (de) |
| NZ (1) | NZ554659A (de) |
| RU (1) | RU2355691C2 (de) |
| TW (1) | TWI365188B (de) |
| WO (1) | WO2006033007A2 (de) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006522088A (ja) * | 2003-03-31 | 2006-09-28 | ファイザー・インク | ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤の塩 |
| US8425929B2 (en) * | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| RU2447889C2 (ru) * | 2005-07-18 | 2012-04-20 | Бипар Сайенсиз, Инк. | Способ лечения рака (варианты) |
| US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| CN101522609A (zh) * | 2006-09-05 | 2009-09-02 | 彼帕科学公司 | 癌症的治疗 |
| CA2662337A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof |
| WO2008114114A2 (en) * | 2007-03-16 | 2008-09-25 | Pfizer Products Inc. | Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition |
| JP2011503111A (ja) * | 2007-11-12 | 2011-01-27 | バイパー サイエンシズ，インコーポレイティド | Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療 |
| CA2705417A1 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| KR20100102637A (ko) * | 2007-12-07 | 2010-09-24 | 바이파 사이언스 인코포레이티드 | 토포이소머라제 억제제 및 ｐａｒｐ 억제제의 병용물에 의한 암의 치료 |
| US20090275608A1 (en) * | 2008-02-04 | 2009-11-05 | Bipar Sciences, Inc. | Methods of diagnosing and treating parp-mediated diseases |
| EP3421030A1 (de) | 2009-11-09 | 2019-01-02 | Allergan, Inc. | Zusammensetzungen und verfahren zur stimulation des haarwuchses |
| DK3150610T3 (da) * | 2010-02-12 | 2019-11-04 | Pfizer | Salte og polymorfer af 8-fluor-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-on |
| EP2569307A2 (de) | 2010-05-10 | 2013-03-20 | Radikal Therapeutics Inc. | Liponsäure- und nitroxidderivate sowie ihre verwendung |
| CA2901280A1 (en) | 2013-02-15 | 2014-08-21 | Allergan, Inc. | Sustained drug delivery implant |
| TWI721947B (zh) * | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| AU2015305696B2 (en) | 2014-08-22 | 2019-08-29 | Pharma& Schweiz Gmbh | High dosage strength tablets of rucaparib |
| ES2879434T3 (es) | 2015-07-23 | 2021-11-22 | Inst Curie | Uso de una combinación de molécula Dbait e inhibidores de PARP para tratamiento del cáncer |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| EP3573990B1 (de) * | 2017-01-24 | 2024-07-10 | Assia Chemical Industries Ltd. | Feste formen von rucaparib und von rucaparib-salzen |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| ES3062817T3 (en) | 2017-05-24 | 2026-04-14 | Univ Pennsylvania | Radiolabeled and fluorescent parp inhibitors for imaging and radiotherapy |
| CA3080657A1 (en) * | 2017-11-03 | 2019-05-09 | Sandoz Ag | Crystalline salt of a tricyclic poly(adp-ribose) polymerase inhibitor |
| CN111989137A (zh) | 2018-01-05 | 2020-11-24 | 赛博克萨1公司 | 用于治疗涉及酸性或缺氧性患病组织的疾病的化合物、组合物和方法 |
| US10442813B2 (en) | 2018-01-30 | 2019-10-15 | RK Pharma Solutions LLC | Polymorphs of rucaparib camsylate and methods of making same |
| KR20200130856A (ko) | 2018-03-13 | 2020-11-20 | 옹쎄오 | 암 치료에서 획득한 내성에 대한 디베이트 분자 |
| KR20220052918A (ko) | 2019-07-10 | 2022-04-28 | 싸이브렉사 2, 인크. | 치료제로서의 사이토톡신의 펩티드 접합체 |
| PH12022550037A1 (en) | 2019-07-10 | 2023-04-12 | Cybrexa 3 Inc | Peptide conjugates of microtubule-targeting agents as therapeutics |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| EP4100125A1 (de) | 2020-02-03 | 2022-12-14 | Sandoz AG | Polymorph von rucaparib-mesylat |
| ES3014370T3 (en) | 2020-04-28 | 2025-04-22 | Rhizen Pharmaceuticals Ag | Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors |
| ES3051838T3 (en) | 2020-07-14 | 2025-12-30 | Assia Chem Ind Ltd | Solid state forms of rucaparib salts |
| WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
| TW202304447A (zh) | 2021-04-08 | 2023-02-01 | 瑞士商瑞森製藥公司 | 聚（ａｄｐ－核糖）聚合酶抑制劑 |
| EP4463232A1 (de) | 2022-01-11 | 2024-11-20 | Assia Chemical Industries Ltd. | Festkörperformen von rucaparibtosylat |
| CN121398822A (zh) | 2023-06-21 | 2026-01-23 | 四方生物科学有限公司 | 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US649554A (en) * | 1899-04-08 | 1900-05-15 | Ferdinand Schwedtmann | Electric switch. |
| GB8806449D0 (en) * | 1988-03-18 | 1988-04-20 | Janssen Pharmaceutica Nv | Antiviral hexahydroimiazo(1 4)benzodiazepin-2-ones |
| EE05006B1 (et) * | 1999-01-11 | 2008-04-15 | Agouron Pharmaceuticals, Inc. | Polü(ADP-riboos)polümeraaside tritsüklilised inhibiitorid ja neid sisaldavad farmatseutilised kompositsioonid |
| JP2006522088A (ja) * | 2003-03-31 | 2006-09-28 | ファイザー・インク | ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤の塩 |
| PL1660095T3 (pl) * | 2003-07-25 | 2010-07-30 | Cancer Research Tech Ltd | Tricykliczne inhibitory PARP |
-
2005
- 2005-09-12 AT AT05799991T patent/ATE551345T1/de active
- 2005-09-12 RU RU2007110026/04A patent/RU2355691C2/ru active
- 2005-09-12 CA CA2581025A patent/CA2581025C/en not_active Expired - Lifetime
- 2005-09-12 BR BRPI0516766-3A patent/BRPI0516766A/pt not_active Application Discontinuation
- 2005-09-12 NZ NZ554659A patent/NZ554659A/en not_active IP Right Cessation
- 2005-09-12 AU AU2005286191A patent/AU2005286191B2/en not_active Ceased
- 2005-09-12 ES ES05799991T patent/ES2382950T3/es not_active Expired - Lifetime
- 2005-09-12 EP EP05799991A patent/EP1799685B1/de not_active Expired - Lifetime
- 2005-09-12 KR KR1020077006422A patent/KR100853601B1/ko not_active Expired - Fee Related
- 2005-09-12 MX MX2007002461A patent/MX2007002461A/es active IP Right Grant
- 2005-09-12 WO PCT/IB2005/002941 patent/WO2006033007A2/en not_active Ceased
- 2005-09-12 JP JP2007531869A patent/JP2008513436A/ja active Pending
- 2005-09-20 AR ARP050103934A patent/AR051296A1/es unknown
- 2005-09-21 US US11/233,835 patent/US7268126B2/en not_active Expired - Lifetime
- 2005-09-21 TW TW094132634A patent/TWI365188B/zh not_active IP Right Cessation
-
2007
- 2007-02-16 NO NO20070920A patent/NO337938B1/no unknown
- 2007-02-20 IL IL181463A patent/IL181463A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP1799685B1 (de) | 2012-03-28 |
| NO337938B1 (no) | 2016-07-11 |
| TW200613305A (en) | 2006-05-01 |
| NZ554659A (en) | 2010-08-27 |
| IL181463A0 (en) | 2007-07-04 |
| AU2005286191A1 (en) | 2006-03-30 |
| BRPI0516766A (pt) | 2008-09-16 |
| JP2008513436A (ja) | 2008-05-01 |
| US20060100198A1 (en) | 2006-05-11 |
| IL181463A (en) | 2012-02-29 |
| WO2006033007A2 (en) | 2006-03-30 |
| RU2355691C2 (ru) | 2009-05-20 |
| US7268126B2 (en) | 2007-09-11 |
| WO2006033007A3 (en) | 2006-11-02 |
| KR100853601B1 (ko) | 2008-08-22 |
| AR051296A1 (es) | 2007-01-03 |
| AU2005286191B2 (en) | 2011-11-17 |
| HK1116483A1 (en) | 2008-12-24 |
| CA2581025C (en) | 2011-06-07 |
| MX2007002461A (es) | 2008-03-13 |
| KR20070089121A (ko) | 2007-08-30 |
| TWI365188B (en) | 2012-06-01 |
| RU2007110026A (ru) | 2008-10-27 |
| CA2581025A1 (en) | 2006-03-30 |
| EP1799685A2 (de) | 2007-06-27 |
| NO20070920L (no) | 2007-03-15 |
| ES2382950T3 (es) | 2012-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2020012I2 (el) | Προφαρμακα των ενωσεων 2,4-πυριμιδινδιαμινης και οι χρησεις αυτων | |
| DE602006020327D1 (de) | 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen | |
| DE602004006169D1 (de) | Substituierte 8'-pyri(mi)dinyl-dihydrospiro-äcycloalkylaminü-pyrimidoä1,2aüpyrimidin-6-onderivate | |
| ATE506362T1 (de) | 1-aza-bicycloä3.3.1ünonane | |
| NO20051281D0 (no) | Sammensetning for anrikning av naeringsmidler | |
| IL185997A0 (en) | Substituted aryl 1.4-pyrazine derivatives background of the invention | |
| DE602006003094D1 (de) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit | |
| DE502006008804D1 (de) | Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen | |
| DE602005015369D1 (de) | Klipp zur gegenseitigen Befestigung von zwei Teilen | |
| ATE466840T1 (de) | Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium | |
| EP1883628A4 (de) | Verbessertes verfahren zur herstellung von 3,5-diethyl-1,2-dihydro-1-phenyl-2-propylpyridin | |
| DE602005017152D1 (de) | Neue 2,6-diaminopyridin-3-on-derivate | |
| DE602004031556D1 (de) | Neue kristalline formen von 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-n-hydroxyethylimidazoä1,2-aüpyridin-6-carbonsäureamidmesylatsalz | |
| BRPI0410638A (pt) | derivados de azitromicina | |
| RU2004132147A (ru) | Адаптоген | |
| FR2888843B1 (fr) | Procede de preparation d'un diarylanthracene. | |
| DK1960510T3 (da) | Ammoniakspecifik 5'-xmp-aminasemutant | |
| ITMI20042402A1 (it) | Processo per la preparazione di n,n-dimetil-n'-feniluree | |
| DE602006018503D1 (de) | Verfahren zur herstellung von 1-benzyl-4-ä(5,6-dimethoxy-1indanon)-2-ylümethylpiperidin oder des hydrochlorids davon | |
| RU2002103738A (ru) | Компонент, обеспечивающий поверхностно-активные свойства композиций-аналогов препаратов для заместительной сурфактантной терапии легочных заболеваний | |
| DE602004009544D1 (de) | Neue 3,3-Dimethyl-5-Cyano-Benzoxepinderivate verwendbar zur Herstellung von 5-Formyl-Benzoxepinderivaten | |
| ITUD20050176A1 (it) | Apparecchiatura di condizionamento dell' aria | |
| ITUD20050179A1 (it) | Apparecchiatura di condizionamento dell'aria | |
| ES1050912Y (es) | Maquina de juego-expendedora de premios. | |
| ITPZ20050003A1 (it) | " free or engaged way on demand" |